➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Merck
Moodys
Medtronic

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,486,437


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,486,437 protect, and when does it expire?

Patent 9,486,437 protects SILENOR and is included in one NDA.

This patent has eleven patent family members in four countries.

Summary for Patent: 9,486,437
Title:Methods of using low-dose doxepin for the improvement of sleep
Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
Inventor(s): Rogowski; Roberta L. (Rancho Santa Fe, CA), Dube; Susan E. (Carlsbad, CA), Jochelson; Philip (San Diego, CA), Kavey; Neil B. (Chappaqua, NY)
Assignee: Pernix Sleep, Inc. (Morristown, NJ) ProCom One, Inc. (San Marcos, TX)
Application Number:14/804,595
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,486,437

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-001 Mar 17, 2010 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF INSOMNIA ⤷  Free Forever Trial
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-002 Mar 17, 2010 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF INSOMNIA ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,486,437

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2687118 ⤷  Free Forever Trial
Canada 2687124 ⤷  Free Forever Trial
European Patent Office 2026792 ⤷  Free Forever Trial
Japan 2009537553 ⤷  Free Forever Trial
Japan 2009537554 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Merck
Harvard Business School
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.